Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-sxzjt Total loading time: 0 Render date: 2024-04-24T23:04:45.989Z Has data issue: false hasContentIssue false

Chapter 8 - Neurobiology of Medication-Resistant Epilepsy

Published online by Cambridge University Press:  20 August 2020

By
Jerome Engel
Edited by
John M. Stern ,
Raman Sankar  and
Michael Sperling
John M. Stern
Affiliation:
Geffen School of Medicine at UCLA, Los Angeles, CA
Raman Sankar
Affiliation:
Geffen School of Medicine at UCLA, Los Angeles, CA
Michael Sperling
Affiliation:
Jefferson Hospital for Neurosciences, Philadelphia, PA
Get access

Summary

According to the World Health Organization, epilepsy accounts for 1% of the global burden of disease, defined as disability-adjusted life years (DALYs), the number of years lost due to disability and premature death [1]. This is equivalent to lung cancer in men and to breast cancer in women. Among primary diseases of the brain, epilepsy ranks with depression and other affective disorders, Alzheimer’s disease and other dementias, and substance abuse.

Type
Chapter
Information
Medication-Resistant Epilepsy
Diagnosis and Treatment
 , pp. 62 - 68
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Löscher, W, Schmidt, D. Modern antiepileptic drug development has failed to deliver ways out of the current dilemma. Epilepsia 2011;52:657–678Google Scholar
Klitgaard, H, Matagne, A, Gobert, J, et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998;353:191–206Google Scholar
Galanopoulou, AS, Buckmaster, PS, Staley, KJ, et al. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 2012;53:571–582Google Scholar
Kwan, P, Brodie, MJ. Early identification of refractory epilepsy. New Engl J Med 2000;342:314–319CrossRefGoogle ScholarPubMed
Berg, AT, Langfitt, J, Shinnar, S, et al. How long does it take for partial epilepsy to become intractable? Neurology 2003;60:186–190Google Scholar
Brunklaus, A, Zuberi, SM. Dravet syndrome–from epileptic encephalopathy to channelopathy. Epilepsia 2014;55:979–984Google Scholar
Helbig, I, Heinzen, EL, Mefford, HC; ILAE Genetics Commission. Primer Part 1-The building blocks of epilepsy genetics. Epilepsia 2016;57:861–868CrossRefGoogle ScholarPubMed
DiMario, FJ, Jr, Sahin, M, Ebrahimi-Fakhari, D. Tuberous sclerosis complex. Pediatr Clin North Am 2015;62:633–648Google Scholar
Wong, M. mTOR as a potential treatment target for epilepsy. Future Neurol 2012;7:537–545CrossRefGoogle ScholarPubMed
Semah, F, Picot, MC, Adam, C, et al. Is the underlying cause of epilepsy a major prognostic factor for recurrence? Neurology 1998;51:1256–1262CrossRefGoogle Scholar
Engel, J Jr, Williamson, PD, Wieser, HG. Mesial temporal lobe epilepsy with hippocampal sclerosis. In: Engel, J Jr, Pedley, TA (eds.), Epilepsy: A Comprehensive Textbook, 2nd edn. Philadelphia, PA: Lippincott-Raven, 2008:2479–2486Google Scholar
Cendes, F. Progressive hippocampal and extrahippocampal atrophy in drug resistant epilepsy. Curr Opin Neurol 2005;18:173–177Google Scholar
Shields, WD, Shewmon, DA, Chugani, HT, Peacock, WJ. The role of surgery in the treatment of infantile spasms. J Epilepsy 1990;(Suppl 3):321–324Google Scholar
Löscher, W, Schmidt, D. Mechanisms of tolerance and drug resistance. In Shorvon, S, Perucca, E, Engel, J Jr (eds.), The Treatment of Epilepsy, 3rd edn. Oxford: Wiley-Blackwell, 2009:109–118CrossRefGoogle ScholarPubMed
Sisodiya, SM, Beck, H, Löscher, W, Vezzani, A. Mechanisms of drug resistance. In: Engel, J Jr, Pedley, TA (eds.), Epilepsy: A Comprehensive Textbook, 2nd edn. Philadelphia, PA: Lippincott-Raven, 2008:1279–1289Google Scholar
Engel, J, Jr. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42:796–803CrossRefGoogle ScholarPubMed
Engel, J, Jr. Report of the ILAE Classification Core Group. Epilepsia 2006;47:1558–1568Google Scholar
Berg, AT, Berkovic, SF, Brodie, MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 2010;51:676–685Google Scholar
Engel, J, Jr. Seizures and Epilepsy, 2nd edn. Oxford: Oxford University Press, 2013:706CrossRefGoogle ScholarPubMed
Engel, J, Jr. Progress in epilepsy: reducing the treatment gap and the promise of biomarkers. Curr Opin Neurol 2008;21:150–154Google Scholar
Lewis, DV, Shinnar, S, Hesdorffer, DC, et al. Hippocampal sclerosis after febrile status epilepticus: the FEBSTAT study. Ann Neurol 2014;75:178–185CrossRefGoogle ScholarPubMed
Coan, AC, Chaudhary, UJ, Grouiller, F, et al. EEG-fMRI in the presurgical evaluation of temporal lobe epilepsy. J Neurol Neurosurg Psychiatry 2015;87(6):642–649CrossRefGoogle ScholarPubMed
Worrell, G, Gotman, J. High-frequency oscillations and other electrophysiological biomarkers of epilepsy: clinical studies. Biomark Med 2011;5(5):557–566Google Scholar
Engel, J Jr, Bragin, A, Staba, R, Mody, I. High-frequency oscillations: what is normal and what is not? Epilepsia 2009;50:598–604Google Scholar
Valentin, A, Arunachalam, R, Mesquita-Rodrigues, A, et al. Late EEG responses triggered by transcranial magnetic stimulation (TMS) in the evaluation of focal epilepsy. Epilepsia 2008;49:470–480Google Scholar
Engel, J, Jr, Pitkänen, A, Loeb, JA, et al. Epilepsy biomarkers. Epilepsia 2013;54(Suppl 4):61–69CrossRefGoogle ScholarPubMed
Kumar, A, Asano, E, Chugani, HT. α-[11C]-methyl-L-tryptophan PET for tracer localization of epileptogenic brain regions: clinical studies. Biomark Med 2011;5:577–584CrossRefGoogle ScholarPubMed
Weissberg, I, Wood, L, Kamintsky, L, et al. Albumin induces excitatory synaptogenesis through astrocytic TGF-β/ALK5 signaling in a model of acquired epilepsy following blood–brain barrier dysfunction. Neurobiol Dis 2015;78:115–125Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×